Bayer Files Lawsuit Against Johnson & Johnson and Janssen Biotech
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy JNJ?
Source: Newsfilter
- Lawsuit Background: Bayer has filed a lawsuit in a New York court against Johnson & Johnson and its subsidiary Janssen Biotech concerning its prostate cancer drug Nubeqa, indicating the company's legal struggles in drug liability.
- Legal Risks: This lawsuit could negatively impact Bayer's market reputation and financial status, particularly as drug liability cases can result in damages reaching millions of dollars, affecting the company's future profitability.
- Industry Impact: The case may trigger widespread scrutiny within the industry regarding drug safety and liability, prompting other pharmaceutical companies to reassess their products' legal compliance, thereby influencing the operational models across the sector.
- Strategic Response: Bayer's legal action demonstrates its proactive legal strategy to protect its interests in the face of competition and market challenges, which may affect its collaborative relationships with other pharmaceutical firms.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 244.120
Low
190.00
Averages
218.50
High
240.00
Current: 244.120
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
JPMorgan ETFs Attract Significant Net Inflows
- Net Inflow Trend: Over the past year, derivative income ETFs have seen significant net inflows, particularly in single-stock ETFs, with the JPMorgan Equity Premium Income ETF and JPMorgan Nasdaq Equity Premium Income ETF collectively managing $78 billion in assets, indicating strong investor demand for high-yield covered call products.
- Investment Strategy Analysis: The JPMorgan Equity Premium Income ETF targets low-volatility stocks and writes out-of-the-money S&P 500 call options to generate monthly income, aiming to reduce downside risk and provide stable cash flow despite challenges like economic slowdown and negative non-farm payroll growth.
- Market Environment Impact: With the U.S. GDP growth rate slowing to just 0.7% in Q4 2025 and the OECD forecasting a 4% inflation rate, these economic conditions are not supportive of rising stock prices, prompting investors to shift towards more defensive investment strategies to mitigate market volatility.
- ETF Comparison: Given the current macroeconomic conditions, the JPMorgan Equity Premium Income ETF is viewed as the better choice due to its low-volatility stocks providing a layer of protection, while the JPMorgan Nasdaq Equity Premium Income ETF, despite an attractive 11.4% yield, carries higher risks due to the volatility of tech stocks.
See More
High Yield Strategies Outperform in Market Pullback
- High Yield Performance: In the current market pullback, high yield and defensive strategies have outperformed the broader market, particularly covered call strategies, which have attracted significant inflows, indicating strong investor demand for income.
- ETF Inflows: Over the past year, derivative income exchange-traded funds (ETFs) have seen substantial net inflows, notably the JPMorgan Equity Premium Income ETF (JEPI) and the JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), which together manage $78 billion in assets, reflecting a market preference for high-yield products.
- Low Volatility Investment: The JPMorgan Equity Premium Income ETF focuses on low-volatility stocks, holding companies like Walmart and Johnson & Johnson, aiming to provide stable cash flow and reduced downside risk, which is crucial in the current environment of slowing economic growth.
- Market Outlook Analysis: Although JEPQ offers a yield of 11.4%, in the context of a slowing economy and labor market, low-volatility stocks may provide better defensive characteristics, making them more suitable for the current uncertain market conditions.
See More
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Johnson & Johnson Stock Supported by Strong Financials
- Strong Financial Performance: Johnson & Johnson reported revenue of $94.2 billion in 2025, a 6% increase, with earnings per share (EPS) reaching $11.03, up 90.5%, reflecting significant profitability improvement post-Kenvue spinoff.
- Consistent Dividend Growth: The company has raised its dividend for 63 consecutive years, with the latest 4.8% increase bringing the quarterly payout to $1.30 per share, resulting in a current yield of approximately 2.1%, bolstering investor confidence in its stock.
- Leading R&D Investment: Johnson & Johnson invested $14.6 billion in research and development last year, achieving 51 drug approvals and launching 15 new med-tech products, underscoring its leadership and innovation in the pharmaceutical sector.
- Existing Risks: Despite strong financials, Johnson & Johnson faces tens of thousands of lawsuits and pricing pressures from the Inflation Reduction Act, which could impact its future profit margins.
See More
Stagflation Fears Rise: Investment Strategies for Resilience
- Surge in Stagflation Searches: Google Trends indicates a 650% increase in searches for 'stagflation 2026' over the past three months, highlighting growing market concerns about economic stagnation and high inflation, prompting investors to reassess potential recession risks.
- Deteriorating Job Data: The U.S. lost 92,000 jobs in February, significantly worse than expected, leading to a 40% probability assessment for a U.S. recession, which could negatively impact consumer spending and corporate earnings.
- Energy Stocks Benefit: In a stagflation scenario, ExxonMobil (XOM), the largest energy company in the U.S., stands to gain as rising oil and gas prices boost its revenues and share price, making it a preferred safe haven for investors amid economic uncertainty.
- Defensive Stock Strategy: Johnson & Johnson (JNJ) and Walmart (WMT) are viewed as top defensive investments in a stagnating economy with high inflation, with J&J benefiting from stable demand for medical products and Walmart leveraging its position in low-priced consumer goods to maintain steady returns during stagflation.
See More
JPMorgan ETFs Attract Significant Net Inflows
- Net Inflow Trend: Over the past year, derivative income ETFs have seen significant net inflows, particularly in single-stock ETFs, with the JPMorgan Equity Premium Income ETF and JPMorgan Nasdaq Equity Premium Income ETF collectively managing $78 billion in assets, indicating strong investor demand for high-yield covered call products.
- Investment Strategy Analysis: The JPMorgan Equity Premium Income ETF targets low-volatility stocks and writes out-of-the-money S&P 500 call options to generate monthly income, aiming to reduce downside risk and provide stable cash flow despite challenges like economic slowdown and negative non-farm payroll growth.
- Market Environment Impact: With the U.S. GDP growth rate slowing to just 0.7% in Q4 2025 and the OECD forecasting a 4% inflation rate, these economic conditions are not supportive of rising stock prices, prompting investors to shift towards more defensive investment strategies to mitigate market volatility.
- ETF Comparison: Given the current macroeconomic conditions, the JPMorgan Equity Premium Income ETF is viewed as the better choice due to its low-volatility stocks providing a layer of protection, while the JPMorgan Nasdaq Equity Premium Income ETF, despite an attractive 11.4% yield, carries higher risks due to the volatility of tech stocks.
See More
High Yield Strategies Outperform in Market Pullback
- High Yield Performance: In the current market pullback, high yield and defensive strategies have outperformed the broader market, particularly covered call strategies, which have attracted significant inflows, indicating strong investor demand for income.
- ETF Inflows: Over the past year, derivative income exchange-traded funds (ETFs) have seen substantial net inflows, notably the JPMorgan Equity Premium Income ETF (JEPI) and the JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), which together manage $78 billion in assets, reflecting a market preference for high-yield products.
- Low Volatility Investment: The JPMorgan Equity Premium Income ETF focuses on low-volatility stocks, holding companies like Walmart and Johnson & Johnson, aiming to provide stable cash flow and reduced downside risk, which is crucial in the current environment of slowing economic growth.
- Market Outlook Analysis: Although JEPQ offers a yield of 11.4%, in the context of a slowing economy and labor market, low-volatility stocks may provide better defensive characteristics, making them more suitable for the current uncertain market conditions.
See More
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Johnson & Johnson Stock Supported by Strong Financials
- Strong Financial Performance: Johnson & Johnson reported revenue of $94.2 billion in 2025, a 6% increase, with earnings per share (EPS) reaching $11.03, up 90.5%, reflecting significant profitability improvement post-Kenvue spinoff.
- Consistent Dividend Growth: The company has raised its dividend for 63 consecutive years, with the latest 4.8% increase bringing the quarterly payout to $1.30 per share, resulting in a current yield of approximately 2.1%, bolstering investor confidence in its stock.
- Leading R&D Investment: Johnson & Johnson invested $14.6 billion in research and development last year, achieving 51 drug approvals and launching 15 new med-tech products, underscoring its leadership and innovation in the pharmaceutical sector.
- Existing Risks: Despite strong financials, Johnson & Johnson faces tens of thousands of lawsuits and pricing pressures from the Inflation Reduction Act, which could impact its future profit margins.
See More
Stagflation Fears Rise: Investment Strategies for Resilience
- Surge in Stagflation Searches: Google Trends indicates a 650% increase in searches for 'stagflation 2026' over the past three months, highlighting growing market concerns about economic stagnation and high inflation, prompting investors to reassess potential recession risks.
- Deteriorating Job Data: The U.S. lost 92,000 jobs in February, significantly worse than expected, leading to a 40% probability assessment for a U.S. recession, which could negatively impact consumer spending and corporate earnings.
- Energy Stocks Benefit: In a stagflation scenario, ExxonMobil (XOM), the largest energy company in the U.S., stands to gain as rising oil and gas prices boost its revenues and share price, making it a preferred safe haven for investors amid economic uncertainty.
- Defensive Stock Strategy: Johnson & Johnson (JNJ) and Walmart (WMT) are viewed as top defensive investments in a stagnating economy with high inflation, with J&J benefiting from stable demand for medical products and Walmart leveraging its position in low-priced consumer goods to maintain steady returns during stagflation.
See More
